Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93,104,451
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
78,283,503
-
Shares change
-
-1,056,860
-
Total reported value, excl. options
-
$2,159,672,726
-
Value change
-
-$41,784,396
-
Put/Call ratio
-
25.6%
-
Number of buys
-
94
-
Number of sells
-
-95
-
Price
-
$27.60
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q4 2021
237 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q4 2021.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78,283,503 shares
of 93,104,451 outstanding shares and own 84.08% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14,684,787 shares), VANGUARD GROUP INC (9,149,521 shares), EARNEST PARTNERS LLC (6,316,365 shares), STATE STREET CORP (4,410,403 shares), WELLINGTON MANAGEMENT GROUP LLP (4,325,775 shares), Camber Capital Management LP (2,750,000 shares), DIMENSIONAL FUND ADVISORS LP (2,635,803 shares), BANK OF AMERICA CORP /DE/ (2,489,302 shares), Artisan Partners Limited Partnership (2,161,219 shares), and PFM Health Sciences, LP (2,025,681 shares).
This table shows the top 191 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.